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Bafilomycin B1 is the archetypal compound of the plecomacro-
lide family of natural products, which include concanamycins,
viranamycins, hygrolidin, elaiophylin, and allied metabolites.[1]
This compound was first isolated from Streptomyces griseus sp.
sulphurus (T 1922) in 1984.[2] The term “plecomacrolide” was
later introduced to describe a subgroup of polyketides with
a 16- or 18-membered macrolactone containing two conjugat-
ed diene units as well as a hemiacetal side chain.[1] These com-
pounds have now been studied extensively as vacuolar ATPase
(V-ATPase) inhibitors and, as such, have shown some promise
as anti-osteoporotics.[3, 4] In addition, synergistic antifungal ac-
tivity of bafilomycin A1 with the calcineurin inhibitor FK506
against the life-threatening fungal pathogen Cryptococcus neo-
formans[5] and inhibition of the release of b-amyloid by bafilo-
mycin A1,
[6] together with the antitumor,[7] antiparasitic,[8] and
immunosuppressant[9] activities of other bafilomycins have
been reported. Despite continued efforts, general toxicity has
kept these compounds from clinical application. Semisynthetic
derivatives have provided some indication that target specifici-
ty can be enhanced.[10] However, extensive manipulation of the
core structure for structure–activity relationship studies re-
mains hampered by the complexity of total synthesis.[11, 12] De-
cades of work in the field of polyketide biosynthesis have
yielded tools to generate subtle changes in the core macrolide
through genetic manipulation.[13, 14] In order to use this knowl-
edge to generate novel analogues, the native biosynthetic
gene cluster sequence must be elucidated. When a bafilomy-
cin-producing organism, Streptomyces lohii, was isolated during
an ongoing drug discovery program in our laboratories, the
characterization of the bafilomycin biosynthetic pathway was
initiated.
To isolate the genes involved in bafilomycin biosynthesis,
a fosmid library was constructed from S. lohii (ATCC BAA-1276,
JCM 14114) genomic DNA. This library was probed for type I
polyketide ketosynthase (KS) domains with a radiolabeled PCR
product amplified from S. lohii gDNA by using degenerate pri-
mers. Colony hybridization experiments revealed 12 KS-positive
fosmids. Initial restriction digestions and Southern hybridiza-
tion experiments revealed two major groups of overlapping
fosmids. One clone from each group was chosen for further
analysis. BLAST analysis[15] of the sequence from a small
number of subclones suggested that one of these representa-
tives contained only type I polyketide synthase (PKS) genes.
Complete sequencing of this clone showed that the domain
organization of the PKS modules exactly matches with a section
of the genetic architecture predicted by the structure of bafilo-
mycin and the typical polyketide rules of colinearity. End
sequencing of the other KS-positive fosmids identified those
containing overlapping sequence. These were also sequenced
to generate a map of the entire gene cluster.
The macrolactone core of bafilomycin is assembled by a
type I PKS system. These genes are arranged as five open read-
ing frames, bafAI–bafAV, spanning 59 kb (Scheme 1, Table 1).
The domain organization of the PKS modules exactly follows
the model suggested by the structure of the core macrolac-
tone and the PKS pattern of colinearity. In addition, acyltrans-
ferase (AT) domains 2 and 6 contain the signature motifs asso-
ciated with the incorporation of malonate.[16] Modules 5 and 11
contain the residues that have been predicted to specify the
selection of methoxymalonate,[17, 18] whereas the remaining ex-
tender modules are specific for methylmalonate;[16] again this
matches the predicted motifs of the bafilomycin structure (see
the Supporting Information). The AT domain of the loading
module was expected to be specific for the incorporation of
isobutyrate, as suggested by the metabolite structure and con-
firmed by precursor-feeding studies.[19] This domain aligns
most closely with the isobutyrate loading domains from the
lipomycin[20, 21] and tautomycin[22] pathways. Downstream of
the core open reading frames is bafH, which encodes a PKS
type II thioesterase (TEII). Homologues of this enzyme have
been found in a number of PKS clusters and are known to pos-
sess an editing role during biosynthesis.[23–25]
The identity of this gene cluster was established by targeted
disruption of bafilomycin production using the REDIRECT
system.[26] When bafAIII was replaced in-frame by the apramy-
[a] Dr. W. Zhang,+ Dr. J. Yan, Y. Liu, F. Bai, Dr. W. Guan, Prof. S. Li
Key Laboratory of Biofuels
Shandong Provincial Key Laboratory of Energy Genetics
Qingdao Institute of Bioenergy and Bioprocess Technology
Chinese Academy of Sciences
189 Songling Road, Qingdao, Shandong 266101 (P. R. China)
E-mail : lishengying@qibebt.ac.cn
[b] Dr. J. L. Fortman,+ Dr. J. C. Carlson, Dr. J. Jia, Prof. D. H. Sherman
Life Sciences Institute, Departments of Medicinal Chemistry,
Chemistry, and Microbiology and Immunology, University of Michigan
210 Washtenaw Avenue, Ann Arbor, MI 48109-2216 (USA)
E-mail : davidhs@umich.edu
[c] Prof. T. Matainaho
School of Medicine and Health Sciences, University of Papua New Guinea
P. O. Box 5623, Boroko, NCD (Papua New Guinea)
[+] These authors contributed equally to this work.
Supporting information for this article is available on the WWW under
http ://dx.doi.org/10.1002/cbic.201200743.
 2013 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim ChemBioChem 2013, 14, 301 – 306 301
CHEMBIOCHEM
COMMUNICATIONS
Table 1. Predicted functions of the open reading frames shown in Scheme 1.
Protein Amino Putative function Nearest homologue (enzyme, origin) Identity/similarity Accession
acids [%] number
BafX 528 acyl CoA ligase MoeA4 [Streptomyces ghanaensis] 72/83 ZP_06574361.1
BafY 514 amide synthetase amide synthetase[Streptomyces tsukubaensis] 78/85 ZP_10067139.1
BafZ 414 5-aminolevulinic acid synthase aminolevulinate synthase [Streptomyces nodosus subsp. 73/83 AAO62615.1
asukaensis]
BafAI 4884 PKS loading module + modules polyketide synthase [Streptomyces neyagawaensis] 62/70 AAZ94387.1
1–3
BafAII 5145 PKS modules 4–6 BFAS2 [S. tsukubaensis] 78/83 ZP_10067132.1
BafAIII 3968 PKS modules 7, 8 BFAS2 [S. tsukubaensis] 79/85 ZP_10067131.1
BafAIV 3511 PKS modules 9, 10 polyketide synthase [Streptomyces scabiei] 62/73 YP_003493865.1
BafAV 2103 PKS module 11 + thioesterase polyketide synthase [Streptomyces clavuligerus] 61/69 ZP_06769488.1
BafB 296 glyceryl-ACP oxidase methoxymalonate biosynthesis protein [S. tsukubaensis] 72/81 ZP_10067126.1
BafC 93 acyl carrier protein (ACP) GalJ [Streptomyces galbus] 69/80 ADE22334.1
BafD 363 acyl-ACP dehydrogenase methoxymalonate biosynthesis protein [S. tsukubaensis] 85/93 ZP_10067124.1
BafE 365 glycerate ACP ligase methoxymalonate biosynthesis protein [S. tsukubaensis] 83/90 ZP_10067123.1
BafF 220 O-methyl transferase O-methyltransferase mdmC [S. clavuligerus] 73/81 ZP_05008783.1
BafG 609 AfsR homologue putative regulator [S. neyagawaensis] 54/64 AAZ94408.1
BafH 253 TEII thioesterase [Streptomyces auratus] 65/76 ZP_10551360.1
ORF1 117 LuxR homologue LuxR family transcriptional regulator [S. tsukubaensis] 65/73 ZP_10067119.1
ORF2 320 putative malonyl transferase acyl-carrier-protein S-malonyltransferase [S. tsukubaensis] 84/90 ZP_10067118.1
ORF3 332 putative CoA ligase hypothetical protein [S. neyagawaensis] 74/83 AAZ94384.1
Scheme 1. A) The organization of open reading frames in the bafilomycin biosynthetic gene cluster. B) The domain organization of the type I polyketide syn-
thases encoded by ORFs BafAI through BafAV.
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cin resistance cassette (genotype confirmed by PCR analysis,
see the Supporting Information), the mutant strain of S. lohii
failed to produce bafilomycins, as demonstrated by HPLC anal-
ysis of culture extracts (Figure 1).
The core macrolactone bafilomycin A1, presumably formed
by the activity of the TE domain in BafAV, acquires enhanced
bioactivity by the addition of a fumarate moiety to the hydoxyl
group on C21 to form bafilomycin C1.
[2] Further potency is pro-
vided by a 2-amino-3-hydroxy-cyclopent-2-enone (C5N) ring
attached to the pendant fumaryl group through an amide
bond formed with the distal carboxylate to give bafilomycin B1
(Scheme 1).
Notably, this C5N moiety, which is present in a variety of sec-
ondary metabolites,[27] often serves as a hydrogen bond donor/
accepter pharmacophore. Its biosynthesis has long been pro-
posed to be from 5-aminolevulinic acid (5-ALA) through an
unusual cyclization process. This putative transformation was
recently confirmed in the ECO-02301 pathway (Scheme 2).[28]
First, the pyridoxal 5’-phosphate (PLP)-dependent 5-ALA syn-
thase (ALAS) ORF34 catalyzes the condensation of succinyl-
CoA and glycine to yield 5-ALA, which is subsequently activat-
ed by the acyl-CoA ligase (ACL) ORF35 to form 5-ALA-CoA.
Next, ORF34 acts again to cyclize 5-ALA-CoA to afford C5N,
avoiding nonenzymatic cyclization to the six-membered ring
2,5-piperidinedione. Finally, the ATP-dependent amide synthe-
tase (AMS) ORF33 is responsible for linking C5N to the carboxyl
group. Interestingly, this enzyme trio is similarly encoded by
a set of three genes located at the 5’-end of the bafilomycin
gene cluster, wherein BafX, BafY, and BafZ are 62/72 %, 40/
55 %, 68/80 % identical/similar to ORF35, ORF33, and ORF34,
respectively, at the protein level. This strongly suggests that
the conversion from bafilomycin C1 to B1 is likely mediated se-
quentially by BafZ!BafX!BafZ!BafY (Scheme 2).
To provide evidence for this proposed tailoring pathway, the
activity of BafZ was characterized in vitro. In addition, this con-
firmed the proposed functionality of BafZ and validated bio-
chemically the identity of the bafilomycin cluster. It is also ex-
pected that BafZ might be useful in industrial fermentation to
overproduce 5-ALA, which has been widely used as a photo-
dynamic medicine to treat various cancers, as a selective bio-
degradable herbicide or insecticide, and as a precursor for the
production of heme-containing enzymes, porphyrin, and vita-
min B12.
[29, 30] Given the similarity between BafZ and ORF34, the
BafZ-catalyzed condensation should be classified as a C4 path-
way (the Shemin pathway) for 5-ALA biosynthesis, which does
not exist in E. coli (the normally selected industrial strain).[30]
Thus, the introduction of the bafZ gene into E. coli would likely
supplement its native C5 pathway of 5-ALA, thereby enhancing
the overall production of 5-ALA. A similar strategy with the
ALAS gene hemA from Rhodobacter sphaeroides has already
achieved significant improvement in 5-ALA productivity.[30, 31]
To characterize the in vitro activity of BafZ, its encoding
gene bafZ was PCR amplified from S. lohii and cloned into the
expression vector pACYCDuet-1. The protein was overexpressed
in E. coli BL21(DE3) and purified by Ni-NTA column chromatog-
raphy (see the Supporting Information). Upon incubation of
purified BafZ (35 mm) with the substrates glycine (5 mm) and
succinyl-CoA (1 mm) at 28 8C for 2 h, significant formation of
a new compound with retention time and molecular weight
(calcd: 132.0655, found: 132.0658) matching those of an au-
thentic standard of 5-ALA was detected during HR-LCMS analy-
sis (Figure 2).
Figure 1. HPLC chromatograms of extracts of wild-type S. lohii compared to
three separate bafAIII gene-disruption mutants.
Scheme 2. Putative pathway for 5-ALA biosynthesis and attachment. a) BafZ
(5-ALA synthase) or ORF34; b) BafX (acyl-CoA ligase) or ORF35; c) BafZ or
ORF34; d) BafY (amide synthetase) or ORF33 for ECO-02301 biosynthesis.
Figure 2. Extracted ion chromatograms (m/z 132.06). A) 5-ALA authentic
standard; B) the BafZ-catalyzed synthesis of 5-ALA from succinyl-CoA and
glycine; C) the negative control with boiled BafZ added to the reaction mix-
ture. The high-resolution mass spectrum of 5-ALA is shown in the Support-
ing Information.
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Sequencing >15 kb upstream and downstream of the de-
fined baf cluster identified no additional ORFs that encode an
enzyme catalyzing attachment of the fumarate moiety. Cluster-
ing of all genes involved in the biosynthesis of a given product
is the paradigm for Streptomyces secondary metabolite produc-
tion. However, separation of the genes producing 2-amino-3-
hydroxy-cyclopent-2-enone from those involved in the produc-
tion of the core polysaccharide in the moenomycin pathway
illustrates one of several exceptions to this rule.[32] Therefore,
this could be the case with the bafilomycin cluster in S. lohii.
Alternatively, it is possible that the amide synthetase BafY also
catalyzes ester bond formation between fumarate and bafilo-
mycin A1; this is supported by the recent report that a nonribo-
somal peptide synthetase condensation enzyme SgcC5 is capa-
ble of catalyzing both amide and ester bond formation.[33] To
test these hypotheses, additional work will be necessary, and is
currently ongoing in our laboratories.
The incorporation of glycerol-derived precursors has been
inferred from feeding studies conducted more than 20 years
ago.[34] Recently, a number of biosynthetic gene clusters utiliz-
ing the glycerol-derived methoxymalonate extender molecule
have been sequenced. Associated with these clusters is an
operon responsible for the biosynthesis of this uncommon
extender unit.[17, 35, 36] Downstream of bafAI–AV are bafB–F, five
open reading frames predicted to encode enzymes responsible
for methoxymalonate biosynthesis (Table 1). BafC is a discrete
acyl carrier protein that is loaded with glycerate, presumably
oxidized from glycerol during primary metabolism by the en-
zyme BafE. The subsequent steps in the generation of meth-
oxymalonate are each proposed to be catalyzed as a BafC-
bound intermediate. First, BafB is proposed to oxidize the 3-hy-
droxy group into an aldehyde, which is subsequently convert-
ed to a carboxylic acid. This conversion is catalyzed by BafD,
an acyl-ACP dehydrogenase.[37] Finally, the a-hydroxyl group is
methylated by BafF, a putative O-methyltransferase. Although
following a genetic organization conserved within several
pathways, each of these genes is most closely related to their
discontinuously distributed counterparts found in the concana-
mycin biosynthetic gene cluster from Streptomyces neyaga-
waensis ATCC 27449.[17]
Based on the results of feeding studies, Schumann et al.
have proposed that methoxymalonate is selected by specific
AT domains directly from the dedicated ACP (BafC).[19] Specific
protein interaction was inferred due to low incorporation of an
N-acetylcysteamine thioester (SNAC) of methoxymalonate.
However, it is possible that methoxymalonate is transferred to
coenzyme A, which then acts as the substrate for the AT. This
scenario is more consistent with the classical mechanisms of
PKS systems. The enzyme encoded by ORF3 could possibly ful-
fill this function. It is predicted to be a CoA ligase and shares
high homology with an enzyme encoded as part of the conca-
namycin biosynthetic gene cluster.[17]
Downstream of the biosynthesis ORFs are a number of
genes encoding putative regulatory elements. BafG is a homo-
logue of AfsR, which has been shown to be a pleiotropic tran-
scriptional activator involved in the regulation of secondary
metabolite biosynthesis in the model organism Streptomyces
coelicolor.[38] Homologues of this protein are associated with
a number of secondary metabolite biosynthesis pathways
within the Streptomyces genus, including the closely related
concanamycin pathway.[17, 39] ORF1 encodes a member of the
LuxR family of transcriptional repressors. Repression is relieved
by the binding of a quorum-sensing molecule, most often a
homoserine lactone.[40] LuxR family proteins are associated
with a number of secondary metabolite biosynthesis clusters,
including the concanamycin system.[17]
In summary, sequencing and analysis of the bafilomycin bio-
synthetic genes has elucidated a new 16-membered plecoma-
crolide pathway identified after the elaiophylin gene cluster.[41]
Recently, the discovery of more bafilomycin derivatives[42–44]
from diverse Streptomyces strains and additional putative bafi-
lomycin biosynthetic genes[45] has suggested broad distribution
of this biosynthetic system. Thus, our work provides an impor-
tant reference for the identification and analysis of analogous
gene clusters, and crucial information for the future engi-
neered biosynthesis of bafilomycin analogues. Moreover, the in
vitro characterization of BafZ expands the pool of 5-ALA syn-
thases, and this might benefit industrial production of 5-ALA.
Experimental Section
Genomic DNA was isolated from S. lohii by using standard Strepto-
myces protocols.[46] A genomic library was constructed in E. coli
Epi300 by using a Fosmid (Epicentre) vector. Initial candidates
were selected from a library of 1152 clones by probing with a radio-
labeled ketosynthase gene fragment. This probe was a heterolo-
gous gene fragment generated by PCR with degenerate KS target-
ing primers 4UU and 5LL (see the Supporting Information) from
S. lohii gDNA as the template.
The sequence was assembled by using Seqman software (DNAS-
tar). Translation analysis was carried out by using the MacVector
open reading frame analysis function. Functional assignment was
accomplished by BLAST analysis[15] against amino acid sequences
contained within the NCBI and EMBL databases. Polyketide syn-
thase domain organization was facilitated by the PKS/NRPS data-
base maintained by the Indian National Institute of Immunology.[47]
Genes in S. lohii were disrupted by using a modified version of the
REDIRECT system.[26] A suicide knockout vector was created by
using fosmid 8D3 from the cluster sequencing effort by replacing
the gene of interest with a selectable disruption cassette. This
fosmid was transferred by interspecies conjugation from E. coli
ET12567 into Streptomyces. Genetic confirmation of the disruption
was accomplished by PCR amplification with genomic DNA as tem-
plate.
Metabolite profiling of the genetically confirmed knockout strains
and one wild-type strain was accomplished by extracting cultures
grown (12 mL) for 72 h. The cultures were centrifuged to remove
cells, and the supernatant was extracted twice with an equal
volume of CH2Cl2. The organic extracts from each culture were
pooled and dried in vacuo, and redissolved in DMSO. Extracts were
analyzed by LC-MS on a C-18 column eluted with a gradient of
acetonitrile in water with 0.1 % formic acid. The mass and retention
times were validated by comparison to an authentic standard pur-
chased from Sigma Aldrich.
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The bafZ gene was amplified from the gDNA of S. lohii by using
the following primers: forward, cgcggatccgatgaaccattacctggagctct-
tctca (BamHI site italicized); reverse, caatgaagctttcagccgtccgttc-
cgggcgacccgtg (HindIII site underlined), and inserted into pACYC-
Duet-1 (Novagen) between the restriction sites of BamHI and Hin-
dIII to afford the expression vector pACYCDuet-1-bafZ. To prepare
BafZ protein, E. coli BL21(DE3) cells carrying pACYCDuet-1-bafZ
were grown at 37 8C in lysogeny broth containing chloramphenicol
(25 mg mL1) until OD6000.4 was reached. Then, isopropyl-b-d-thi-
ogalactopyranoside (IPTG; 0.1 mm final concentration) was added
to initiate protein overexpression. The cells were cultured at 16 8C
for another 16 h, collected by centrifugation (5000 g, 10 min, 4 8C),
resuspended in lysis buffer (30 mL, 20 mm HEPES, pH 8.0, 0.5 m
NaCl, 5 mm imidazole), and lysed by sonication on ice. After
a high-speed centrifugation (40 000 g, 30 min, 4 8C) to remove the
cell debris, Ni-NTA agarose resin (1 mL, Qiagen) was added to the
supernatant, and the solution was mixed for 1 h at 4 8C. Next, the
resin with bound proteins was loaded onto a gravity flow column,
washed with wash buffer (50 mL, 20 mm HEPES, pH 8.0, 0.5 m NaCl,
20 mm imidazole), and eluted with elution buffer (20 mm HEPES,
pH 8.0, 0.5 m NaCl, 250 mm imidazole). The purified BafZ was
buffer exchanged into desalting buffer (50 mm NaH2PO4, 10 % glyc-
erol) on a PD-10 column (GE Healthcare). The final proteins were
flash frozen in liquid nitrogen and stored at 80 8C.
The in vitro BafZ assay was performed according to Zhang et al.[28]
Briefly, purified BafZ (35 mm) was incubated with glycine (5 mm)
and succinyl-CoA (1 mm) in a total reaction volume of 100 mL at
28 8C. After 2 h, methanol (100 mL) was added to stop the reaction.
After removal of the precipitated proteins by centrifugation
(20 000 g, 15 min), the supernatant was subjected to HR-LCMS anal-
ysis (Dionex Ultimate 3000 with Bruker maxis Q-TOF) by using
a BEH Amide column (2.1 mm  100 mm, 1.7 mm, Waters). Acetoni-
trile (solvent B) and water/5 % acetonitrile (solvent A) were used as
the mobile phases with a flow rate of 0.20 mL min1. The program
was as follow: 90–70 % B in A over 10 min, 70 % B for 5 min, 70–
90 % B over 1 min, 90 % B for 4 min.
Additional experimental details are available in the Supporting In-
formation. The nucleotide sequence reported here has been de-
posited in GenBank under the accession number GU390405.
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